title: Oxatomide in the treatment of chronic urticaria. A double-blind placebo-controlled trial.
abstract: Oxatomide was evaluated in a double-blind study of 35 patients with chronic urticaria. For 5 weeks patients received at random either 30 mg oxatomide b.i.d. or a placebo. Oxatomide significantly reduced not only the duration of the attacks but also the severity of erythema, lesions and itching. This lower level of suffering was clearly reflected by a diminished need for additional antiallergic medication. The overall response to treatment was rated excellent or good in 72% of the oxatomide-treated patients against only 23% of the controls which is a significant difference. Sleepiness was reported in 1 patient of each group.
mesh_terms: D000293:Adolescent; D000328:Adult; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D010919:Placebos; D014581:Urticaria / Q000188:drug therapy*
chemical_list: D010879:Piperazines; D010919:Placebos; C015408:oxatomide